{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:36:26Z","timestamp":1784896586085,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004636","name":"Myeloma UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C1298\/A8362"],"award-info":[{"award-number":["C1298\/A8362"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C1298\/A8362"],"award-info":[{"award-number":["C1298\/A8362"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"David Forbes-Nixon Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite recent advances in therapy, multiple myeloma essentially remains an incurable malignancy. Targeting tumour-specific essential genes, which constitute a druggable dependency, potentially offers a strategy for developing new therapeutic agents to treat MM and overcome drug resistance. To explore this possibility, we analysed DepMap project data identifying 23 MM essential genes and examined the relationship between their expression and patient outcome in three independent series totalling 1503 cases. The expression of<jats:italic>TCF3<\/jats:italic>and<jats:italic>FLVCR1<\/jats:italic>were both significantly associated with progression-free survival.<jats:italic>IKBKB<\/jats:italic>is already a drug target in other diseases, offering the prospect of repurposing to treat MM, while<jats:italic>PIM2<\/jats:italic>is currently being investigated as a treatment for the disease. Our analysis supports the rationale of using large-scale genetic perturbation screens to guide the development of new therapeutic agents for MM.<\/jats:p>","DOI":"10.1038\/s41598-022-16940-7","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T10:03:23Z","timestamp":1658829803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Exploiting gene dependency to inform drug development for multiple myeloma"],"prefix":"10.1038","volume":"12","author":[{"given":"Molly","family":"Went","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuc H.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin F.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Houlston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"issue":"2","key":"16940_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","volume":"33","author":"AK Dutta","year":"2019","unstructured":"Dutta, A. K. et al. Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability. Leukemia 33(2), 457\u2013468 (2019).","journal-title":"Leukemia"},{"issue":"5","key":"16940_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner, H., Gondos, A. & Pulte, D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111(5), 2521\u20132526 (2008).","journal-title":"Blood"},{"issue":"7753","key":"16940_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR\u2013Cas9 screens. Nature 568(7753), 511\u2013516 (2019).","journal-title":"Nature"},{"issue":"3","key":"16940_CR4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170(3), 564\u201376.e16 (2017).","journal-title":"Cell"},{"key":"16940_CR5","unstructured":"Foundation MMR. Multiple Myeloma Research Foundation Researcher Gateway 2020 [cited 2021 January 2021]. Available from: https:\/\/research.themmrf.org\/."},{"issue":"8","key":"16940_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.1665","volume":"28","author":"L Shi","year":"2010","unstructured":"Shi, L. et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat. Biotechnol. 28(8), 827\u2013838 (2010).","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"16940_CR7","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2012-04-421883","volume":"120","author":"SZ Usmani","year":"2012","unstructured":"Usmani, S. Z. et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: Influence of thalidomide and lenalidomide during maintenance. Blood 120(8), 1597\u20131600 (2012).","journal-title":"Blood"},{"key":"16940_CR8","doi-asserted-by":"publisher","first-page":"e57116","DOI":"10.7554\/eLife.57116","volume":"10","author":"K Shimada","year":"2021","unstructured":"Shimada, K., Bachman, J. A., Muhlich, J. L. & Mitchison, T. J. shinyDepMap, a tool to identify targetable cancer genes and their functional connections from Cancer Dependency Map data. Elife 10, e57116 (2021).","journal-title":"Elife"},{"key":"16940_CR9","doi-asserted-by":"publisher","unstructured":"Broad. DepMap 2020 20Q2 Public https:\/\/doi.org\/10.6084\/m9.figshare.12280541.v4.","DOI":"10.6084\/m9.figshare.12280541.v4"},{"key":"16940_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-1-4939-3578-9_4","volume":"1418","author":"MR Carlson","year":"2016","unstructured":"Carlson, M. R., Pag\u00e8s, H., Arora, S., Obenchain, V. & Morgan, M. Genomic annotation resources in R\/bioconductor. Methods Mol. Biol. (Clifton, NJ). 1418, 67\u201390 (2016).","journal-title":"Methods Mol. Biol. (Clifton, NJ)."},{"issue":"19","key":"16940_CR11","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/bioinformatics\/btq431","volume":"26","author":"BS Carvalho","year":"2010","unstructured":"Carvalho, B. S. & Irizarry, R. A. A framework for oligonucleotide microarray preprocessing. Bioinformatics 26(19), 2363\u20132367 (2010).","journal-title":"Bioinformatics"},{"issue":"4","key":"16940_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi, S., R\u00fccker, G. & Schwarzer, G. How to perform a meta-analysis with R: A practical tutorial. Evid. Based Ment. Health 22(4), 153 (2019).","journal-title":"Evid. Based Ment. Health"},{"issue":"1","key":"16940_CR13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.) 57(1), 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"},{"issue":"D1","key":"16940_CR14","doi-asserted-by":"publisher","first-page":"D985","DOI":"10.1093\/nar\/gkw1055","volume":"45","author":"G Koscielny","year":"2017","unstructured":"Koscielny, G. et al. Open targets: A platform for therapeutic target identification and validation. Nucleic Acids Res. 45(D1), D985\u2013D994 (2017).","journal-title":"Nucleic Acids Res."},{"issue":"W1","key":"16940_CR15","doi-asserted-by":"publisher","first-page":"W612","DOI":"10.1093\/nar\/gkv352","volume":"43","author":"M Davies","year":"2015","unstructured":"Davies, M. et al. ChEMBL web services: Streamlining access to drug discovery data and utilities. Nucleic Acids Res. 43(W1), W612\u2013W620 (2015).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"16940_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100(1), 57\u201370 (2000).","journal-title":"Cell"},{"issue":"6","key":"16940_CR17","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy Jr","year":"2007","unstructured":"Shaughnessy, J. D. Jr. et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109(6), 2276\u20132284 (2007).","journal-title":"Blood"},{"issue":"11","key":"16940_CR18","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper, R. et al. A gene expression signature for high-risk multiple myeloma. Leukemia 26(11), 2406\u20132413 (2012).","journal-title":"Leukemia"},{"key":"16940_CR19","unstructured":"Slyper M, Shahar A Fau - Bar-Ziv A, Bar-Ziv A Fau - Granit RZ, Granit Rz Fau - Hamburger T, Hamburger T Fau - Maly B, Maly B Fau - Peretz T, et al. Control of breast cancer growth and initiation by the stem cell-associated transcription factor TCF3. (1538\u20137445 (Electronic))."},{"issue":"10","key":"16940_CR20","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1158\/0008-5472.CAN-18-2156","volume":"79","author":"S Sohoni","year":"2019","unstructured":"Sohoni, S. et al. Elevated heme synthesis and uptake underpin intensified oxidative metabolism and tumorigenic functions in non-small cell lung cancer cells. Cancer Res. 79(10), 2511\u20132525 (2019).","journal-title":"Cancer Res."},{"issue":"2","key":"16940_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cell.2019.06.005","volume":"178","author":"C Wiel","year":"2019","unstructured":"Wiel, C. et al. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell 178(2), 330\u201345.e22 (2019).","journal-title":"Cell"},{"issue":"5","key":"16940_CR22","first-page":"1559","volume":"52","author":"C Peng","year":"2018","unstructured":"Peng, C. et al. FLVCR1 promotes the proliferation and tumorigenicity of synovial sarcoma through inhibiting apoptosis and autophagy. Int. J. Oncol. 52(5), 1559\u20131568 (2018).","journal-title":"Int. J. Oncol."},{"issue":"2","key":"16940_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2013.088211","volume":"99","author":"G An","year":"2014","unstructured":"An, G. et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica 99(2), 353\u2013359 (2014).","journal-title":"Haematologica"},{"issue":"3","key":"16940_CR24","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.3324\/haematol.2015.136929","volume":"101","author":"N Weinhold","year":"2016","unstructured":"Weinhold, N. et al. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica 101(3), e116\u2013e119 (2016).","journal-title":"Haematologica"},{"issue":"5","key":"16940_CR25","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura, I. et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108(5), 1724\u20131732 (2006).","journal-title":"Blood"},{"issue":"6","key":"16940_CR26","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108(6), 2020\u20132028 (2006).","journal-title":"Blood"},{"issue":"10","key":"16940_CR27","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","volume":"106","author":"N Weinhold","year":"2021","unstructured":"Weinhold, N. et al. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma-a meta-analysis of 2,596 trial patients. Haematologica 106(10), 2754 (2021).","journal-title":"Haematologica"},{"issue":"39","key":"16940_CR28","doi-asserted-by":"publisher","first-page":"26960","DOI":"10.1074\/jbc.M114.598763","volume":"289","author":"X Kai","year":"2014","unstructured":"Kai, X. et al. I\u03baB kinase \u03b2 (IKBKB) mutations in lymphomas that constitutively activate canonical nuclear factor \u03baB (NF\u03baB) signaling. J. Biol. Chem. 289(39), 26960\u201326972 (2014).","journal-title":"J. Biol. Chem."},{"issue":"3","key":"16940_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2014-05-577130","volume":"125","author":"YX Zhu","year":"2015","unstructured":"Zhu, Y. X. et al. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. Blood 125(3), 483\u2013491 (2015).","journal-title":"Blood"},{"issue":"7","key":"16940_CR30","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/ajmg.a.38274","volume":"173","author":"KD Khandelwal","year":"2017","unstructured":"Khandelwal, K. D. et al. Identification of a de novo variant in CHUK in a patient with an EEC\/AEC syndrome-like phenotype and hypogammaglobulinemia. Am. J. Med. Genet. A 173(7), 1813\u20131820 (2017).","journal-title":"Am. J. Med. Genet. A"},{"issue":"2","key":"16940_CR31","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1038\/cddis.2014.49","volume":"5","author":"C Stolfi","year":"2014","unstructured":"Stolfi, C. et al. A functional role for Smad7 in sustaining colon cancer cell growth and survival. Cell Death Dis. 5(2), e1073 (2014).","journal-title":"Cell Death Dis."},{"issue":"9","key":"16940_CR32","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.7150\/jca.53134","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Xiu, J., Ren, C. & Yu, Z. Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics. J. Cancer 12(9), 2570\u20132581 (2021).","journal-title":"J. Cancer"},{"issue":"8","key":"16940_CR33","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1038\/bcj.2016.73","volume":"6","author":"J Ramachandran","year":"2016","unstructured":"Ramachandran, J., Santo, L., Siu, K. T., Panaroni, C. & Raje, N. Pim2 is important for regulating DNA damage response in multiple myeloma cells. Blood Cancer J. 6(8), e462 (2016).","journal-title":"Blood Cancer J."},{"issue":"15","key":"16940_CR34","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","volume":"116","author":"BA Walker","year":"2010","unstructured":"Walker, B. A. et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116(15), e56-65 (2010).","journal-title":"Blood"},{"key":"16940_CR35","unstructured":"Landgren, O., Rajkumar, S. V. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. (1078\u20130432 (Print))."},{"key":"16940_CR36","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1038\/bcj.2012.37","volume":"9","author":"A Kalff","year":"2012","unstructured":"Kalff, A. & Spencer, A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: Prognostic implications and current clinical strategies. Blood Cancer J. 9, e89 (2012).","journal-title":"Blood Cancer J."},{"issue":"4","key":"16940_CR37","first-page":"207","volume":"62","author":"D Derudas","year":"2020","unstructured":"Derudas, D., Capraro, F., Martinelli, G. & Cerchione, C. Old and new generation immunomodulatory drugs in multiple myeloma. Panminerva Med. 62(4), 207\u2013219 (2020).","journal-title":"Panminerva Med."},{"key":"16940_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/0-306-46877-8_4","volume-title":"Human Cell Culture Vol. III. Cancer Cell Lines Part 3: Leukemias and Lymphomas","author":"HNK Jernberg-Wiklund","year":"2002","unstructured":"Jernberg-Wiklund, H. N. K. Multiple myeloma cell lines. In Human Cell Culture Vol. III. Cancer Cell Lines Part 3: Leukemias and Lymphomas (eds Masters, J. R. W. & Palsson, B. O.) 81\u2013155 (Springer, Netherlands, 2002)."},{"issue":"8","key":"16940_CR39","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47(8), 856\u2013860 (2015).","journal-title":"Nat. Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16940-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16940-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16940-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T22:12:58Z","timestamp":1727647978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16940-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["16940"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-16940-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"5 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12696"}}